Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

MUC5B promoter variant identified as a risk factor for RA-ILD

Philippe Dieudé discusses the results of a study demonstrating that the MUC5B promoter variant rs35705950 is linked to rheumatoid arthritis-associated interstitial disease susceptibility (3:01).

Related content

22-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

MUC5B promoter variant tied to RA-ILD risk

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Interstitial lung disease risk linked to rheumatoid arthritis disease severity
Image Credits